Institute of Human Genetics, UMR 9002 Centre National de la Recherche Scientifique, University of Montpellier, Montpellier, 34396 Montpellier, France.
Department of Biological Hematology, CHU Montpellier, 34295 Montpellier, France.
Int J Mol Sci. 2020 Oct 28;21(21):8047. doi: 10.3390/ijms21218047.
Plasma cells (PC) are the main effectors of adaptive immunity, responsible for producing antibodies to defend the body against pathogens. They are the result of a complex highly regulated cell differentiation process, taking place in several anatomical locations and involving unique genetic events. Pathologically, PC can undergo tumorigenesis and cause a group of diseases known as plasma cell dyscrasias, including multiple myeloma (MM). MM is a severe disease with poor prognosis that is characterized by the accumulation of malignant PC within the bone marrow, as well as high clinical and molecular heterogeneity. MM patients frequently develop resistance to treatment, leading to relapse. Polycomb group (PcG) proteins are epigenetic regulators involved in cell fate and carcinogenesis. The emerging roles of PcG in PC differentiation and myelomagenesis position them as potential therapeutic targets in MM. Here, we focus on the roles of PcG proteins in normal and malignant plasma cells, as well as their therapeutic implications.
浆细胞（PC）是适应性免疫的主要效应细胞，负责产生抗体来保护身体免受病原体侵害。它们是一个复杂的高度调节的细胞分化过程的结果，发生在几个解剖部位，并涉及独特的遗传事件。在病理上，PC 可以发生肿瘤发生，并导致一组称为浆细胞异常的疾病，包括多发性骨髓瘤（MM）。MM 是一种预后不良的严重疾病，其特征是恶性 PC 在骨髓内积聚，以及高临床和分子异质性。MM 患者经常对治疗产生耐药性，导致复发。多梳组（PcG）蛋白是参与细胞命运和致癌作用的表观遗传调节剂。PcG 在 PC 分化和骨髓瘤发生中的新兴作用将其作为 MM 的潜在治疗靶点。在这里，我们重点介绍 PcG 蛋白在正常和恶性浆细胞中的作用及其治疗意义。
